% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln May 5, 2014 11:31 PM Flag

    GHDX @ ASCO meeting Presentation

    Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
    New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS)
    REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, reinforce the company's successful approach to understanding tumor biology—now across four different cancer types—and highlight the following:

    Unique value and practice-changing impact of the Oncotype DX test in breast cancer
    Breadth of clinical evidence for the Oncotype DX test in colon cancer
    Continued adoption and clinical utility of Oncotype DX across healthcare systems worldwide
    Further evidence of the robustness of the Oncotype DX prostate cancer test

26.11-0.48(-1.81%)Jun 24 4:00 PMEDT